maintenance therapy with regorafenib
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Primary objectives: The objective of this study is to evaluate efficacy and safety of regorafenib in the maintenance of the response in patients with metastatic colorectal (CRC) RAS wild type after first line therapy (fluoropirimidine-based plus anti-EGFR Abs). The primary efficacy endpoint of this study is Progression Free Survival (PFS) defined as the time(days) from randomization for maintenance therapy with study drug to PD or death whichever comes first. Primary endpoints: Progression-free Survival (PFS)
创建时间：
2014-12-15
